Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03338790
Title An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer
Recruitment Active, not recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

prostate adenocarcinoma

Therapies

Enzalutamide + Nivolumab

Nivolumab + Rucaparib

Docetaxel + Nivolumab

Age Groups: adult | senior
Covered Countries USA | FRA | ESP | DEU | CAN


No variant requirements are available.